Publications by authors named "Ruth Witt"

Claim this Profile
L
LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration.
Cornelis M van Tilburg, Lindsay B Kilburn, Sébastien Perreault, Rene Schmidt, Amedeo A Azizi, Ruth Witt, Olaf Witt

BMC Cancer· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcome of Children and Adolescents With Relapsed/Refractory/Progressive Malignancies Treated With Molecularly Informed Targeted Drugs in the Pediatric Precision Oncology Registry INFORM.
Anna-Elisa Heipertz, Kristian W Pajtler, Elke Pfaff, Kathrin Schramm, Mirjam Blattner-Johnson, Ruth Witt, Olaf Witt

JCO Precis Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets.
Cornelis M van Tilburg, Elke Pfaff, Kristian W Pajtler, Karin P S Langenberg, Petra Fiesel, Ruth Witt, Olaf Witt

Cancer Discov· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Study of Regulatory Challenges of Pediatric Oncology Phase I/II Trial Submissions and Guidance on Protocol Development.
Lydia Beck, Ruth Witt, Martina Nesper-Brock, Till Milde, Simone Hettmer, Olaf Witt

Clin Pharmacol Ther· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies.
Cornelis M van Tilburg, Ruth Witt, Melanie Heiss, Kristian W Pajtler, Christoph Plass, Olaf Witt

BMC Cancer· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia.
Cornelis M van Tilburg, Till Milde, Ruth Witt, Jonas Ecker, Thomas Hielscher, Olaf Witt

Clin Epigenetics· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brainstem biopsy in pediatric diffuse intrinsic pontine glioma in the era of precision medicine: the INFORM study experience.
Elke Pfaff, Ahmed El Damaty, Gnana Prakash Balasubramanian, Mirjam Blattner-Johnson, Barbara C Worst, Hendrik Witt, Ruth Witt, Olaf Witt

Eur J Cancer· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Monitoring futility and efficacy in phase II trials with Bayesian posterior distributions-A calibration approach.
Annette Kopp-Schneider, Manuel Wiesenfarth, Ruth Witt, Dominic Edelmann, Olaf Witt

Biom J· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study.
Barbara C Worst, Cornelis M van Tilburg, Gnana Prakash Balasubramanian, Petra Fiesel, Ruth Witt, Olaf Witt

Eur J Cancer· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pediatric Targeted Therapy: Clinical Feasibility of Personalized Diagnostics in Children with Relapsed and Progressive Tumors.
Florian Selt, Alica Deiß, Andrey Korshunov, David Capper, Hendrik Witt, Ruth Witt, Olaf Witt

Brain Pathol· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis